$7 billion generic market available as patents expire
$7 billion generic market available as patents expire
The generic company that can persuade the Food and Drug Administration it’s got a bioequivalent version of Procardia XL or Cardizem CD stands to reap a sizable profit. Those two products top the list of drugs available with expired patents but that have yet to experience generic competition. Combined, Procardia XL and Cardizem CD make up $1.8 billion of this $7 billion gold mine.
The market also includes such top sellers as Premarin ($700 million in sales), Seldane ($271 million), Trental ($193 million), and Retrovir ($128 million). Some older products yet to see generic competition include Dilantin ($194 million), Trandate ($28 million), and Dilaudid ($13 million). Meclomen also has no generic competition, but with just $81,000 in sales in 1995, it’s not likely to land a suitor.
Numerous products by Ciba-Geigy, including Lithobid, Transderm-Scop, Lamprene, Cytadren, Cataflam, Lopressor Oros, and Estraderm are up for competition. Other leading drug companies with a number of products on the line include Lilly (Dobutrex, Permax, Kefurox and Humulin), Hoechst Marion Roussel (Cardizem CD, Seldane, Seldane D, Trental, Nicoderm, Tenuate, Bricanyl and Nicorette Gum), and Fisons, whose entire line of cromolyn sodium products Nasalcrom, Opticrom and Intal could be picked off by generic companies.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.